# US 2024/0392031 A1 · Caix targeting il-12 fusion proteins and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392031 A1
- Document ID: US20240392031A1
- Status: Published application
- Kind: A1
- Application number: 18/607,049
- Filed: 2024-03-15
- Published: 2024-11-28
- Earliest claimed: 2021-09-17
- Assignees: Bicara Therapeutics Inc.
- Applicants: Bicara Therapeutics Inc.
- Inventors: Jaya BHATNAGAR; Arvind Vittal GOSWAMI; Harish Kumar TRIPURANA; Pradip NAIR; Ramakrishnan Melarkode SUBBARAMAN; Shiv Ram KRISHN; Srinivas Reddy BOREDDY; Reshmi NAIR; Avanish K. VARSHNEY; Seng-Lai TAN
- Web page: https://patentgrep.com/patent/US20240392031A1

## CPC

- C07K 16/30: from tumour cells
- A61P 35/00: Antineoplastic agents
- C07K 14/5434: {IL-12}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/522: CH1 domain
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are IL-12p40 and IL-12p35 polypeptides and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the IL-12p40 and IL-12p35 polypeptides and compositions. Further provided herein are fusion proteins (e.g., antibody fusion proteins) that comprise an IL-12p40 polypeptide (e.g., an IL-12p40 polypeptide described herein) and/or IL-12p35 polypeptide (e.g., an IL-12p35 polypeptide described herein). The IL-12p40 polypeptides, IL-12p35 polypeptides, and fusion proteins provided herein are useful in pharmaceutical compositions and methods of treating diseases (e.g., cancer).

## Claims

### Claim 1

A human interleukin 12 p40 (hIL-12p40) polypeptide comprising an amino acid sequence (a) at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 33; and (b) comprising or consisting of an amino acid substitution at each of amino acid positions (i) W37, F82, and K219; (ii) W37, F82, and K217; (iii) K106, K217, and K219; (iv) W37 and F82; (v) W37 and K217; (vi) W37 and K219; (vii) W37 and K106; (viii) F82 and K106; (xiv) F82 and K217; (xv) F82 and K219; (xvi) K217 and K219; (xvii) K106 and K217; or (xviii) K106 and K219, amino acid numbering relative to the amino acid sequence of SEQ ID NO: 32.

### Claim at position 2

2-16. (canceled)

### Claim 17

A human interleukin 12 p35 (hIL-12p35) polypeptide comprising an amino acid sequence (a) at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 31; and (b) comprises or consists of an amino acid modification at one or more of the following amino acid positions E60, F61, P63, K150, F188, Y189A, amino acid numbering relative to the amino acid sequence of SEQ ID NO: 30.

### Claim at position 4

18-21. (canceled)

### Claim 22

A hIL-12p35 polypeptide, wherein the amino acid sequence of the hIL-12p35 polypeptide comprises or consists of a deletion of amino acids A55-K92, N50-K92, M51-K92, L52-K92, Q53-K92, K54-K92, N50-N93, M51-N93, L52-N93, Q53-N93, K54-N93, N50-E94, M51-E94, L52-E94, Q53-E94, K54-E94, N50-S95, M51-S95, L52-S95, Q53-S95, K54-S95, N50-C96, M51-C96, L52-C96, Q53-C96, K54-C96, N50-L97, M51-L97, L52-L97, Q53-L97, K54-L97, N50-P87, M51-P87, L52-P87, Q53-P87, K54-P87, N50-L88, M51-L88, L52-L88, Q53-L88, K54-L88, N50-E89, M51-E89, L52-E89, Q53-E89, K54-E89, N50-L90, M51-L90, L52-L90, Q53-L90, K54-L90, N50-T91, M51-T91, L52-T91, Q53-T91, K54-T91, R56-K92, Q57-K92, T58-K92, L59-K92, E60-K92 A55-N93, R56-N93, Q57-N93, T58-N93, L59-N93, E60-N93, A55-E94, R56-E94, Q57-E94, T58-E94, L59-E94, E60-E94, A55-S95, R56-S95, Q57-S95, T58-S95, L59-S95, E60-S95, A55-C96, R56-C96, Q57-C96, T58-C96, L59-C96, E60-C96, A55-L97, R56-L97, Q57-L97, T58-L97, L59-L97, E60-L97, A55-P87, R56-P87, Q57-P87, T58-P87, L59-P87, E60-P87, A55-L88, R56-L88, Q57-L88, T58-L88, L59-L88, E60-L88, A55-E89, R56-E89, Q57-E89, T58-E89, L59-E89, E60-E89, A55-L90, R56-L90, Q57-L90, T58-L90, L59-L90, E60-L90, A55-T91, R56-T91, Q57-T91, T58-T91, L59-T91, or E60-T91 (amino acid numbering relative to the amino acid sequence of SEQ ID NO: 30), and other than the deletion of amino acids A55-K92, N50-K92, M51-K92, L52-K92, Q53-K92, K54-K92, N50-N93, M51-N93, L52-N93, Q53-N93, K54-N93, N50-E94, M51-E94, L52-E94, Q53-E94, K54-E94, N50-S95, M51-S95, L52-S95, Q53-S95, K54-S95, N50-C96, M51-C96, L52-C96, Q53-C96, K54-C96, N50-L97, M51-L97, L52-L97, Q53-L97, K54-L97, N50-P87, M51-P87, L52-P87, Q53-P87, K54-P87, N50-L88, M51-L88, L52-L88, Q53-L88, K54-L88, N50-E89, M51-E89, L52-E89, Q53-E89, K54-E89, N50-L90, M51-L90, L52-L90, Q53-L90, K54-L90, N50-T91, M51-T91, L52-T91, Q53-T91, K54-T91, R56-K92, Q57-K92, T58-K92, L59-K92, E60-K92 A55-N93, R56-N93, Q57-N93, T58-N93, L59-N93, E60-N93, A55-E94, R56-E94, Q57-E94, T58-E94, L59-E94, E60-E94, A55-S95, R56-S95, Q57-S95, T58-S95, L59-S95, E60-S95, A55-C96, R56-C96, Q57-C96, T58-C96, L59-C96, E60-C96, A55-L97, R56-L97, Q57-L97, T58-L97, L59-L97, E60-L97, A55-P87, R56-P87, Q57-P87, T58-P87, L59-P87, E60-P87, A55-L88, R56-L88, Q57-L88, T58-L88, L59-L88, E60-L88, A55-E89, R56-E89, Q57-E89, T58-E89, L59-E89, E60-E89, A55-L90, R56-L90, Q57-L90, T58-L90, L59-L90, E60-L90, A55-T91, R56-T91, Q57-T91, T58-T91, L59-T91, or E60-T91 the amino acid sequence of the polypeptide is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 31.

### Claim at position 6

-24. (canceled)

### Claim 25 (depends on 1)

A single chain hIL-12 (schIL-12) polypeptide comprising the hIL-12p40 polypeptide of claim 1 operably connected to a hIL-12p35 polypeptide.

### Claim at position 8

-28. (canceled)

### Claim 29 (depends on 17)

A schIL-12 polypeptide comprising the hIL-12p35 polypeptide of claim 17 operably connected to a hIL-12p40 polypeptide.

### Claim at position 10

-35. (canceled)

### Claim 36 (depends on 1)

A fusion protein comprising
a. the hIL-12p40 polypeptide of claim 1,
b. a hIL-12p35 polypeptide; and
c. a heterologous moiety.

### Claim 37 (depends on 17)

A fusion protein comprising
a. a hIL-12p40 polypeptide;
b. the hIL-12p35 polypeptide of claim 17; and
c. a heterologous moiety.

### Claim at position 13

-117. (canceled)

### Claim 118 (depends on 1)

A fusion protein comprising
a. a full-length antibody that specifically binds a hTAA comprising:
i. a first light chain comprising from N- to C-terminus a light chain variable region (VL) region and a light chain constant region (CL) region;
ii. a first heavy chain comprising from N- to C-terminus a heavy chain variable region (VH) region, a CH1 region, a hinge region, a CH2 region, and a CH3 region;
iii. a second heavy chain comprising from N- to C-terminus a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region;
iv. a second light chain comprising from N- to C-terminus a VL region and a VH region;
wherein the first light chain and the first heavy chain associate to form a first antigen binding domain;
wherein the second light chain and the second heavy chain associate to form a second antigen binding domain; and
wherein the first heavy chain and the second heavy chain associate to form a dimer;
b. the hIL-12p40 polypeptide of claim 1,
c. a hIL-12p35 polypeptide;
wherein the CH3 region of the first heavy chain of the full-length antibody comprises one or more amino acid modification relative to the amino acid sequence of a reference CH3 region that does not contain the one or more amino acid modification;
wherein the CH3 region of the second heavy chain of the of the full-length antibody comprises one or more amino acid modification relative to the amino acid sequence of a reference CH3 region that does not contain the one or more amino acid modification;
wherein the one or more amino acid modification in the CH3 region of the first heavy chain of the full-length antibody is different from the one or more amino acid modification in the CH3 region of the second heavy chain of the full-length antibody;
wherein the one or more amino acid modification in the CH3 region of the first heavy chain of the full-length antibody and the one or more amino acid modification in the CH3 region of the second heavy chain of the full-length antibody promote heterodimerization of the first and second heavy chain of the full-length antibody;
wherein the N-terminus of the hIL-12p40 polypeptide is operably connected to the C-terminus of the CH3 region of the first heavy chain via a first peptide linker; and
wherein the N-terminus of the hIL-12p35 polypeptide is operably connected to the C-terminus of the CH3 region of the second heavy chain via a second peptide linker.

### Claim at position 15

-130. (canceled)

### Claim 131 (depends on 1)

A fusion protein comprising:
a. a first polypeptide comprising a first light chain comprising from N- to C-terminus a VL region and a CL region;
b. a second polypeptide comprising from N- to C-terminus: (i) a first heavy chain comprising from N- to C-terminus a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region; (ii) a first peptide linker, and (iii) the hIL-12p40 polypeptide of claim 1;
c. third polypeptide comprising from N- to C-terminus: (i) a second heavy chain comprising from N- to C-terminus a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region, (ii) a second peptide linker; and (iii) a hIL-12p35 polypeptide; and
d. a fourth polypeptide comprising a second light chain comprising from N- to C-terminus a VL region and a CL region;
wherein the VL of the first light chain and the VH of the first heavy chain associate to form a first antigen binding domain that specifically binds a first hTAA;
wherein the CH3 region of the first heavy chain comprises one or more amino acid modification relative to the amino acid sequence of a reference CH3 region that does not contain the one or more amino acid modification;
wherein the CH3 region of the second heavy chain comprises one or more amino acid modification relative to the amino acid sequence of a reference CH3 region that does not contain the one or more amino acid modification;
wherein the one or more amino acid modification in the CH3 region of the first heavy chain of the full-length antibody is different from the one or more amino acid modification in the CH3 region of the second heavy chain of the full-length antibody;
wherein the one or more amino acid modification in the CH3 region of the first heavy chain of the full-length antibody and the one or more amino acid modification in the CH3 region of the second heavy chain of the full-length antibody promote heterodimerization of the first and second heavy chain of the full-length antibody.

### Claim at position 17

-143. (canceled)

### Claim 144

An antibody (or antigen binding domain thereof) that specifically binds hCAIX and comprises a VH and VL, wherein the amino acid sequence of the VH is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 3-9; and the amino acid sequence of the VL is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 10-17.

### Claim 145

(canceled)

### Claim 146 (depends on 1)

A polynucleotide encoding the hIL-12p40 polypeptide of claim 1.

### Claim at position 21

-148. (canceled)

### Claim 149 (depends on 146)

An expression vector comprising the polynucleotide of claim 146.

### Claim 150

(canceled)

### Claim 151 (depends on 1)

A host cell comprising the hIL-12p40 polypeptide of claim 1.

### Claim 152 (depends on 1)

A carrier comprising the hIL-12p40 polypeptide of claim 1.

### Claim 153

(canceled)

### Claim 154 (depends on 1)

A pharmaceutical composition comprising the hIL-12p40 polypeptide of claim 1, and a pharmaceutically acceptable excipient.

### Claim 155 (depends on 1)

A kit comprising the hIL-12p40 polypeptide of claim 1.

### Claim 156 (depends on 1)

A method of making the hIL-12p40 polypeptide of claim 1, the method comprising:
a. introducing into a population of in vitro or ex vivo cells a polynucleotide encoding the hIL-12p40 polypeptide,
b. culturing the population of cells under conditions sufficient for the population of cells to express the multispecific protein; and
c. optionally isolating and/or purifying the hIL-12p40 polypeptide.

### Claim 157 (depends on 1)

A method of delivering a polypeptide to a subject, the method comprising administering the hIL-12p40 polypeptide of claim 1 to the subject, in an amount and for a time sufficient to deliver the hIL-12p40 polypeptide to the subject.

### Claim 158 (depends on 1)

A method of stimulating T-cell or NK cell effector function in a subject, the method comprising administering the hIL-12p40 polypeptide of claim 1 to the subject, in an amount and for a time sufficient to stimulate T-cell or NK cell effector function in the subject.

### Claim 159 (depends on 1)

A method of preventing or treating a cancer in a subject, the method comprising administering the hIL-12p40 polypeptide of claim 1 to the subject in need thereof, in an amount and for a time sufficient to prevent or treat the cancer in the subject.

### Claim at position 33

-162. (canceled)

### Claim 163

A method of determining the expression of CAIX in cells of a cancer in a subject, the method comprising:
a. obtaining the sample from a subject, wherein the sample does not contain cancer cells (or does not contain a substantial number of cancer cells), and
b. determining the presence or absence of soluble CAIX (or a fragment or variant thereof) in the sample.

### Claim 164

A method of diagnosing a subject with a cancer comprising cancer cells expressing CAIX, the method comprising:
a. obtaining the sample from a subject, wherein the sample does not contain cancer cells (or does not contain a substantial number of cancer cells),
b. determining the presence or absence of soluble CAIX (or a fragment or variant thereof) in the sample; and
c. diagnosing the subject as having a cancer comprising cancer cells expressing CAIX, if soluble CAIX is determined to be present in the sample.

### Claim 165 (depends on 1)

A method of treating a cancer in a subject, the method comprising:
a. receiving test results that determined the presence of soluble CAIX in a sample from a subject, wherein the sample does not contain cancer cells (or does not contain a substantial number of cancer cells);
b. diagnosing the subject as having a cancer comprising cancer cells expressing CAIX; and
c. administering the hIL-12p40 polypeptide of claim 1 to the subject in need thereof, in an amount and for a time sufficient to treat the cancer in the subject.

### Claim at position 37

-169. (canceled)

### Claim 170 (depends on 22)

A fusion protein comprising
a. a hIL-12p40 polypeptide;
b. the hIL-12p35 polypeptide of claim 22; and
c. a heterologous moiety.
